-
2024-515062-13-00
5
2025-01-14
acute ischemic stroke caused by occlusion of a large vessel
-
2023-509883-89-00
5
2025-01-09
Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
-
2024-512798-29-00
5
2025-01-07
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-518316-39-00
10
2024-11-18
Acute lymphoblastic leukemia
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2023-504708-27-00
5
2024-11-02
electronic cigarette cessation
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-503394-37-00
5
2024-10-23
Acute Myeloid Leucaemia
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2023-508429-29-00
4
2024-09-26
Progressive Pulmonary Fibrosis
-
2024-511688-27-00
4
2024-09-19
Myelofibrosis
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-508005-24-00
5
2024-08-01
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2023-504910-31-00
5
2024-07-15
Non-small Cell Lung Cancer (NSCLC)
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.